Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle

Comparison Between Agonist Trigger With HCG Luteal Phase Supplementation vs HCG Trigger With Progesterone Luteal Phase Supplementation in Antagonist Controlled HyperstimulationCycle Regarding Clinical Pregnancy Rate

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04846218

Enrollment

100

Registered

2021-04-15

Start date

2016-12-31

Completion date

2020-06-30

Last updated

2021-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Brief summary

The aim of the current study is to compare agonist trigger and HCG luteal support vs standard HCG trigger and progesterone luteal supplementation in antagonist controlled hyperstimulation cycle as regards to clinical pregnancy rate.

Detailed description

Prospective Interventional randomized pilotstudy on patients undergoing controlled ovarian hyperstimulation. All patients will receive a fixed dose of 150-300 IU recombinant FSH (Gonal-F; Sereno Laboratories,Madrid, Spain) for ovarian stimulation according to age, BMI and antral follicle count (AFC). After 6 days of stimulation, FSH will be adjusted according to ovarian response. Premature LH surge will be prevented with 0.25 mg of a GnRH antagonist (Cetrotide; Serono International, Geneva, Switzerland) starting on day 6 when two or more follicles reach a size of 18-20 mm, trigger of ovulation will be done and followed by luteal phase support according to the protocol assigned for each group. Group 1: A single dose of 0.2 mg triptorelin (Decapeptyl® Ipsen Pharmaceutical Company, France) and follow up with daily 125 IU HCG injections Group 2: A single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg IM (Prontogest®).

Interventions

DRUGhCG

DRUGProgesterone

DRUGTriptorelin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 39 Years

Healthy volunteers

Inclusion criteria

* Age between 20 and 39 years. * Body mass index between 18 and 30. * Unexplained infertility or male factor infertility

Exclusion criteria

* Endocrinological disorder eg.:hyperprolactenemia, Hypo or hyper thyrodism * More than 2 previous attemptsof IVF * Any uterine anatomical anomaly.

Design outcomes

Primary

Measure	Time frame	Description
Clinical pregnancy rate	1 year	Clinical pregnancy diagnosed by pregnancy test and ultrasound

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026